Clearpoint Neuro is trading at $13.00 (15.5% down) after its second-quarter earnings disappointed and management lowered full-year 2026 revenue guidance.
- While revenue growth exceeded expectations, the company reported a wider net loss per share and cited partner-driven gene therapy delays and shifting investment priorities for the reduced outlook.
- The decline appears to be company-specific rather than macro-driven, as broader U.S. equity futures are trading modestly higher during the pre-market session.